Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study
Cancer Science · 2025
DOI: 10.1111/cas.16360 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Science, 2025. Verfasst von Fudong Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Biomarkers, Tumor, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Hospitals Authority Youth Programme, Beijing Municipal Science and Technology Commission.
Abstract (Originalsprache)
Lung cancer is one of the most prevalent cancers worldwide, yet only approximately 16% of patients are diagnosed in early stage, highlighting the urgent need for novel, highly accurate detection models. In our study, patients with suspected lung cancer or lung disease, as identified through radiographic imaging, along with healthy individuals, were consecutively recruited from Beijing Chest Hospital. Circulating free DNA (cfDNA) was extracted from plasma samples, and low‐depth whole‐genome sequencing was performed to identify fragmentomic features for model construction. A total of 265 participants were prospectively enrolled, comprising 124 lung cancer patients and 141 noncancer individuals. The model we developed was based on four cfDNA fragmentation characteristics, including 20‐bp breakpoint nucleotides motif, fragmentation size coverage, fragmentation size distribution, and copy number variation. In an independent test cohort, the model achieved an area under the curve (AUC) of 0.861 (95% CI: 0.781–0.942) and demonstrated a sensitivity of 70% (95% CI: 53.5%–83.4%) at a specificity of 89.4% (95% CI: 76.9%–96.5%). Notably, the model was also effective in detecting early‐stage cancer, with an AUC of 0.808 (95% CI: 0.69–0.925). In summary, our lung cancer detection model shows strong screening capabilities by leveraging four cfDNA fragmentation characteristics, exhibiting robust performance in early cancer diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
- Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, China.
- Thoracic Minimally Invasive Treatment Center, Beijing Chest Hospital, Capital Medical University, Beijing, China.
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
- Department of Medicine, Beijing USCI Medical Laboratory, Beijing, China.
ORCID-Profile: Nanying Che
Förderung
- National Natural Science Foundation of China
- Beijing Hospitals Authority Youth Programme
- Beijing Municipal Science and Technology Commission
- Public Welfare Development and Reform Pilot Project of Beijing Municipal Medical Research Institutes
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
Zitieren
APA
Xu, F., Wang, C., Li, H., Yu, B., Chang, L., Wang, F., Long, C., Bai, L., Zhao, H., & Che, N. (2025). Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study. Cancer Science. https://doi.org/10.1111/cas.16360
Vancouver
Xu F, Wang C, Li H, Yu B, Chang L, Wang F, et al. Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study. Cancer Science. 2025. doi:10.1111/cas.16360
BibTeX
@article{Xu2025,
author = {Xu, Fudong and Wang, Chong and Li, Hongxia and Yu, Bo and Chang, Luyuan and Wang, Feng and Long, Chaolian and Bai, Ling and Zhao, Hanqing and Che, Nanying},
title = {Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.16360}
}
EUVIMED